Results 121 to 130 of about 2,146 (159)
Ravulizumab for the treatment of myasthenia gravis
Expert Opinion on Biological Therapy, 2023 Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response.
Renato Mantegazza, Fiammetta Vanoli
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Monitoring Ravulizumab effect on complement assays
Journal of Immunological Methods, 2021Ravulizumab is a new C5 inhibitor therapeutic monoclonal antibody with a longer half-life than eculizumab. Monitoring complete complement blockade by eculizumab has allowed personalized therapy in specific settings. Similar action is expected with ravulizumab. Ravulizumab has 4 different amino acids from eculizumab, which allow greater affinity for the
Paula Ladwig +2 more
exaly +3 more sources
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
Journal of Neurology, 2023 Abstract Introduction The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized, placebo-controlled period (RCP) of the CHAMPION MG study, ravulizumab provided rapid and sustained efficacy and was well tolerated ...
James F Howard +2 more
exaly +5 more sources
Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Expert Opinion on Biological Therapy, 2020Introduction: Eculizumab, which is indicated to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), is a life-changing, life-saving therapy that decreases intravascular hemolysis and thrombosis and improves survival. Some eculizumab-treated patients, however, experience breakthrough hemolysis; and overall, the burden of the treatment ...
Jong Wook Lee, Austin Kulasekararaj
exaly +3 more sources
Canadian Journal of Health Technologies, 2023
CADTH recommends that Ultomiris be reimbursed by public drug plans for the treatment of neuromyelitis optica spectrum disorder (NMOSD) if certain conditions are met. Ultomiris should only be covered to treat adult patients with anti–aquaporin 4 (AQP4) antibody–positive NMOSD.
openaire +1 more source
CADTH recommends that Ultomiris be reimbursed by public drug plans for the treatment of neuromyelitis optica spectrum disorder (NMOSD) if certain conditions are met. Ultomiris should only be covered to treat adult patients with anti–aquaporin 4 (AQP4) antibody–positive NMOSD.
openaire +1 more source
Ravulizumab: A Review in Generalised Myasthenia Gravis
Drugs, 2023Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) to be approved in several countries globally, for adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive (AChR Ab+).
openaire +2 more sources
Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
NEJM Evidence, 2022BACKGROUND: Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating autoimmune disease. Activation of the complement system by autoantibodies against the postsynaptic acetylcholine receptor (AChR) leads to destruction of the postsynaptic membrane and disruption of neuromuscular transmission.
Tuan, Vu +9 more
openaire +2 more sources
Ravulizumab: First Global Approval
Drugs, 2019Ravulizumab (ravulizumab-cwvz; ULTOMIRIS™), a humanized monoclonal antibody, is a complement C5 inhibitor developed by Alexion Pharmaceuticals for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS).
openaire +2 more sources
Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria
Expert Opinion on Orphan Drugs, 2020Eculizumab, the anti-C5 monoclonal antibody therapeutic, has revolutionized the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH), and has shown efficacy in other complement-mediated disorders...
Hayeong Rho, Richard A Wells
openaire +1 more source
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source